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Abstract 
Polymeric micelles have received considerable interest for their use as drug delivery vehicles for hydrophobic 
drug solubilisation. Inorganic metallic nanoparticles have already been exploited clinically in diagnostics for 
their contrast ability, using magnetic resonance imaging. The combination of these two platforms results in a 
multifunctional drug carrier for image-guided drug delivery. Here we report the synthesis and evaluation of a 
new class of poly(allylamine) (PAA) polymer grafted with hydrophobic oxadiazole (Ox) pendant group in a 5% 
molar monomer:pendant ratio. Further, the thiol-containing pendant group facilitated the attachment of hybrid 
iron oxide-gold nanoparticles (HNPs) via dative covalent bonding. Physicochemical characterisation of both 
PAA-Ox5 and PAA-Ox5-HNP polymers was carried out using elemental analysis, nuclear magnetic resonance 
(NMR), fourier transform infrared spectroscopy (FTIR) and photon correlation spectroscopy (PCS). The drug 
loading potential of these novel aggregates was investigated, through direct conjugation of hydrophilic and 
encapsulation of hydrophobic drugs, respectively. The model hydrophobic drugs 2,6-diisopropylphenol 
(propofol) and (2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-
3,4'-dione (griseofulvin), and the chemotherapeutic agents bisnapthalamidopropyldiaminooctane (BNIPDaoct) 
and 6-Thioguanine (6-TG) were used. The data showed that the addition of HNPs onto the PAA-Ox5 structure 
resulted in aggregates of 175 nm in diameter. The PAA-Ox5-HNP nano-aggregates were capable of high drug 
solubilisation capacities (25.79 mgmL-1, 1.68 mgmL-1 and 0.92 mgmL-1) for propofol, griseofulvin and 
BNIPDaoct, respectively. 6-TG was also successfully conjugated into the polymer structure (2.8 mgmL-1). In 
vitro assays on human pancreatic adenocarcinoma cells (BxPC-3) showed increased drug uptake and decreased 
IC50 values using the novel formulations compared with free drug. This study highlights the potential of PAA-
Ox5-HNP as a bi-functional imaging and drug delivery platform. 
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Introduction 
Polymeric amphiphiles have proven to be an excellent alternative to low molecular weight surfactants for drug 
solubilisation [1-3]. In aqueous environments, they spontaneously aggregate into micelle-like aggregates via 
hydrophobic-hydrophobic interactions [4]. Polymeric nano-aggregates can be formed from a diverse range of 
architectures including block copolymers [5], graft polymers [6], star shaped polymers [7] and dendrimers [8]. 
Graft polymers consist of a water-soluble homopolymer backbone with hydrophobic groups ‘grafted’ onto this 
to form a comb shaped structure [9]. Commonly, poly(ethylenimine) [10], poly(allylamine) [11] and chitosan 
[12] backbones have been used in the formation of these macromolecules. Previous work has reported the 
promising potential of poly(allylamine) (PAA) grafted with cholesteryl and dansyl moieties to act as universal 
hydrophobic drug solubilizers [13].  Model drugs included 2,6-diisopropylphenol (propofol), 11β-11,17,21-
trihydroxypregna-1,4-diene-3,20-dione (prednisolone) and (2S,6’R)-7-chloro-2’,4,6-trimethoxy-6’-methyl-
3H,4’H-spiro[1-benzofuran-2,1’-cyclohex[2]ene]-3,4’-dione (griseofulvin) [13]. 
In recent years, magnetic iron oxide nanoparticles have been widely studied for biomedical and electronic 
applications. These applications include: detection at the cellular level, imaging using nuclear magnetic 
resonance imaging (MRI), targeted drug delivery and gene therapy, waste water treatment and electronics [14-
18]. Iron oxide nanoparticles possess a large surface area to volume ratio due to their nano-size, a low surface 
charge at physiological pH and they also aggregate in solution due to their inherent magnetic properties. The 
subsequent stability problems in solution can be overcome by surface engineering of the particles with coatings 
such as silica and polymers [14,19]. However, in the last few years, increasing concern has arisen over the 
safety of polymer coated iron oxide nanoparticles [20-22]. This culminated in the withdrawal of Feridex® from 
use in humans in the United Kingdom in 2012. It is proposed that the degradation of the flexible polymer 
coating leads to iron oxide core exposure, resulting in free radical production and, ultimately, cellular stress or 
mortality [21,23,24].  The need for a robust coating has therefore led to the recent development of gold-iron 
oxide hybrid nanoparticles (HNPs) [25]. Gold is renowned for its chemical stability and biocompatibility in the 
nano-shell structure [26]. Gold nanostructures can be further functionalised using molecules that possess a thiol 
group which are strongly adsorbed onto the gold surface [27]. Previous studies investigating HNP fabrication 
have shown that the insertion of an organic intermediate between the iron oxide core and gold coating helps to 
preserve the unique characteristics of both the iron oxide and gold components [25,28]. A recent study has also 
investigated the effect of the hybrid composition on HNP physicochemical properties, i.e., changing the core 
size, coating thickness etc. in order to harvest optimal particles [28]. Additionally, in vitro biocompatibility 
testing has reported no considerable HNP degradation or toxic effect [29]. Thus, indicating the suitability of 
these HNPs for biomedical application. 
The incorporation of polymeric amphiphiles and HNPs into a single platform may therefore create a bi-
functional system capable of dual imaging and drug delivery of active pharmaceutical ingredients. In this study 
we aim to graft water-soluble PAA with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol (oxadiazole, Ox) in a 5% 
monomer:pendant group ratio (PAA-Ox5). The oxadiazole moiety is hydrophobic due to its aromatic structure 
and also possesses a thiol (SH) functionality. This pendant group will act as a site of permanent conjugation for 
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the HNPs; achieved through the strong dative covalent attachment between the thiol and colloidal gold surface. 
The physicochemical properties of the novel PAA-Ox5 will be investigated both before and after HNP 
conjugation.  The potential of these nano-aggregates as drug cargo carriers in the aqueous environment will also 
be investigated. The model hydrophobic drugs propofol and griseofulvin will be used to determine optimal drug 
solubilisation parameters. Propofol is the most commonly used intravenous anaesthetic agent in the world owing 
to its rapid onset, short half-life and minimal side-effect profile [30].  The highly lipophilic nature of the 
compound (logP 4.16) hinders its formulation as an aqueous-based injection. Early propofol formulations 
utilised Cremophor EL (a non-ionic surfactant) in water but were associated with characteristic adverse effects 
including severe anaphylactic hypersensitivity reactions [31].  Subsequently, propofol was reformulated into a 
microemulsion formulation (e.g. Diprivan®) which is still the current preparation used clinically [32].  
However, some limitations remain, including pain upon injection and support for bacterial growth [33].  
Griseofulvin is a lipophilic drug with an aqueous solubility of 30 µgmL-1 at 25 ºC [34]. The antifungal 
properties of griseofulvin are exploited in both animals and humans for the treatment of dermatophyte infections 
[35,36]. Its hydrophobic nature results in a low aqueous solubility in the gastrointestinal (GI) tract resulting in 
poor oral bioavailability [37,38]. Griseofulvin is currently administered orally in microcrystalline preparations 
with prescribed doses of 500-1000 mgday-1 [39]. However, a great deal of inter- and intra-subject variation is 
experienced, perhaps due to erratic and incomplete absorption of the drug from the GI tract [40].  The novel 
anticancer drug bisnaphthalimidopropyldiaminooctane (BNIPDaoct) has been reported to possess great potential 
as a cytotoxic agent in pancreatic cancer treatment [41,42]. BNIPDaoct has shown negligible aqueous solubility 
and as a result toxic solvents such as dimethyl sulfoxide (DMSO) have been required in order to dissolve the 
drug [41,43]. Here, we will investigate the potential of the two PAA derivatives in BNIPDaoct solubilisation 
using the optimal formulation strategies determined. Additionally, the potential of these novel nano-aggregates 
to act as hydrophilic drug carriers will be investigated using 6-thioguanine (6-TG). 6-TG is an antitumour agent 
used clinically in the treatment of leukaemia [44]. However, its association with a large number of serious side 
effects such as ulcerative colitis and bone marrow toxicity, has seen its use decline in recent years [45].  6-TG 
will be conjugated onto the PAA-Ox5-HNP surface via dative covalent bonding in a similar process to the 
polymer HNP conjugation. The drug conjugation capacity will be determined using PAA-Ox5 as a control.  In 
vitro studies in human pancreatic adenocarcinoma (BxPC-3) cells will determine the effect of drug 
incorporation into the PAA amphiphiles on both drug uptake and cytotoxicity. 
 
Materials and Methods 
Materials 
Poly(allylamine) (PAA), 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol and auric chloride dihydrate were 
purchased from AlfaAesar (UK). Dialysis tubing membranes were purchased from Medicell International Ltd. 
(UK). Syringe filters (0.22 µm), acetonitrile, methanol and dimethyl sulfoxide (DMSO) were purchased from 
Fisher Scientific (UK). Foetal bovine serum, Roswell Park Memorial Institute Medium (RPMI) 1640, trypsin 
and penicillin streptomycin were purchased from Life Technologies (UK). Human pancreatic adenocarcinoma 
(BxPC-3) cells were purchased from ATCC (USA). All other chemicals were purchased from Sigma-Aldrich 
(UK). 
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Methods 
PAA-Ox5 synthesis 
PAA was reacted in 1:0.05 molar feed with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol (Oxadiazole, Ox) 
(monomer: pendant). Briefly, the PAA was dissolved in 1:1 (v/v) methanol: chloroform with stirring followed 
by the addition of triethylamine. The reaction was stirred at room temperature for 0.5 h. The 5-(4-chlorophenyl)-
1,3,4-oxadiazole-2-thiol was dissolved in 1:1 (v/v) methanol:chloroform and added drop wise to the polymer 
solution over 0.5 h. The reaction was stirred at 37°C for 18 h. After evaporating the solvent on a reduced 
pressure using a rotary evaporator the polymer residue was washed three times with diethyl ether and dried 
thoroughly. The residue was dissolved in deionised water and exhaustively dialysed using visking membrane 
12-14 kDa against deionised water for 24 h. The resultant solution was freeze-dried. Polymer structure was 
characterised using proton nuclear magnetic spectroscopy (1H NMR, 400MHz at 25oC) in deuterated water 
(D2O) (Bruker, UK), attenuated total reflectance-fourier transform infrared spectroscopy (ATR-FTIR) (Nicolette 
IS50, Thermo-Fisher UK) and elemental analysis on a Perkin Elmer series 2 elemental analyser (Perkin Elmer, 
UK). 
 
HNP synthesis 
Sodium hydroxide (NaOH) and potassium nitrate (KNO3) were dissolved in deionised water and heated to 
reflux at 90 ˚C for 1 h under a nitrogen (N2) atmosphere. Iron (III) sulfate heptahydrate (FeSO4.7H2O) was 
dissolved in sulfuric acid (H2SO4) and added to the reaction. The reaction was stirred at 90 ˚C for 24 h. The 
precipitate was cooled and washed in deionised water. A poly(ethylenimine) (PEI) intermediate was attached 
electrostatically via probe sonication with magnetic particles in deionised water. Gold seeds (2 nm) were 
attached through electrostatic interaction to the polymer followed by iterative reduction of auric chloride 
dehydrate (HAuCl4) onto the particle surface forming a complete shell. The final particles were washed 
extensively with deionised water to ensure excess gold was removed from the solution before resuspending in 
deionised water. Metal content was determined using inductively coupled plasma – optical emission 
spectroscopy (ICP-OES). An acid digestion was carried out in concentrated nitric acid (HNO3, 1:5 sample: acid) 
and the samples were diluted with deionised water prior to analysis. A calibration was run using iron and gold 
standard solutions 0.5 – 5 mgmL-1 (R2=0.9999). The concentration of HNPs used for all experiments indicates 
the concentration of Fe.  Maximum UV absorbance (λmax) of HNPs was measured using a UV-2600 UV-
VIS(NIR) with an ISR-2600 Plus Integrated sphere (Shimadzu, Germany) of samples in aqueous solution. 
Solutions were analysed in quartz cuvettes, absorbance scans were carried out between 400 – 800 nm. 
Hydrodynamic diameter and polydispersity index were estimated using photon correlation spectroscopy (PCS) 
(Zetasizer Nano-ZS, Malvern Instruments, UK). All measurements were carried out at 25 °C (n=3). Zeta 
potential measurements were carried out to determine surface charge using the same instrument. Transmission 
electron microscopy (TEM) was used to visualise the morphology and diameter of particles on formvar-coated 
copper grids using a JEOL JEM-1230 microscope with ANAlysis software (JEOL, Japan). Magnetic 
characterisation was carried out in a Quantum Design MPMS-XL SQUID magnetometer as previously 
described [28]. Briefly, zero-field-cooled warming (ZFCW) and field-cooled-warming (FCW) and cooling 
(FCC) curves were measured between 10 and 280 K, in a field H = 8 kA/m. Magnetisation vs. applied field 
hysteresis loops were collected at 10 and 250 K in applied fields up to 4 MA/m. 
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PAA-Ox5-HNP conjugation 
A 5 mgmL-1 PAA-Ox5 (10 mL) solution was prepared in deionised water with probe sonication for 10 min. 
HNPs (500 µL) were added into solution and the mixture was sonicated for a further 10 min.  
 
Characterisation of PAA-Ox5 and PAA-Ox5-HNP nano-aggregates 
Nano-aggregates were formed in aqueous solution via probe sonication. Solutions were filtered using 0.22 µm 
syringe filters prior to further analysis. The critical aggregation concentration (CAC) was determined using a 
hydrophobic methyl orange UV probe in an adaptation of Uchegbu’s method [46]. Briefly, a stock solution of 
methyl orange (25 μM) was prepared with sodium tetraborate buffer (0.02 M, pH 9.4) in deionised water. 
Polymer solutions (0.00145 - 3 mgmL-1) were made up using the methyl orange solution as the diluent. Each 
sample was probe sonicated for 5 min and allowed to cool to room temperature. The polymer solutions were 
measured in a UV-2600 UV-VIS(NIR) spectrometer (Shimadzu, Germany) and their maximum absorbance 
recorded (350-600 nm). The methyl orange stock solution was used as the control. The presence of 
hypsochromic shift was determined by comparing the polymer solution wavelength maxima with the λmax of 
methyl orange stock solution (463 nm). Photon correlation spectroscopy, zeta potential measurement, TEM 
imaging and magnetic characterisation was carried out as previously described.  
 
Drug loading of nano-aggregates 
Probe sonication was used to incorporate drug molecules into the self-assemblies as previously reported [11,14]. 
Aqueous polymer solutions (1, 3 and 6 mgmL-1) were probe sonicated for 10 min.  Hydrophobic drugs (propofol 
and griseofulvin) were added to solution using initial drug: polymer feed ratios of 1:1, 5:1 and 10:1. The 
solutions were sonicated for a further 10 min before cooling to room temperature. The solutions were filtered 
using 0.22 μm syringe filters to remove any excess unsolubilised drug molecules. Anticancer therapeutic agents 
6-TG and BNIPDaoct were incorporated into the nano-aggregate structure using the optimal polymer 
concentration / drug feed ratio determined using the model drug studies.  
Propofol, griseofulvin and 6-TG concentration were determined via absorbance measurement at 272 nm, 292 
nm and 330 nm in the UV-Vis spectrophotometer, respectively. Propofol and griseofulvin measurements were 
achieved upon sample dilution in acetonitrile and methanol, respectively. 6-TG measurements were carried out 
in aqueous samples. BNIPDaoct concentration was measured using a JASCO PH-980 coupled with a JASCO 
FP-920 fluorescent HPLC (JASCO, Japan). A ODS H: Optimal column (Metlab, UK) of 150 mm x 4.6 mm x 5 
µm was used with mobile phase consisting of 55:45 (v:v) buffer:acetonitrile. The buffer was composed of 0.46 g 
octane sulfonic acid and 1.64 g anhydrous sodium acetate made up to 200 mL with deionised water and pH 
adjusted to pH 4.6. The mobile phase was run at 1 mLmin-1 and sample analysis carried out at excitation and 
emission wavelengths of 234 nm (Ex.) and 394 nm (Em.) respectively. BNIPDaoct measurements were carried 
out in samples diluted in 50:50 (v:v) DMSO:H2O. All measurements were carried out at room temperature 
(25oC) and the drug encapsulation concentrations deduced in respect to calibration graphs.  For all formulations 
the % drug loading capacity (LC) and % drug encapsulation efficiency (EE) were calculated. The optimal 
6 
 
formulations for each drug molecule were analysed using PCS, zeta potential measurement and TEM, as 
previously described. The formulations were freeze-dried and ATR-FTIR spectra obtained. 
 
In vitro drug release from nano-aggregates 
The formulation (2 mL) was pipetted inside dialysis tubing (MW cut off = 12-14 kDa) and dialysed against PBS 
under ‘sink conditions’ (200 mL, 0.2 M) at 37 ºC with stirring. At various time points, 1 mL of the external PBS 
was extracted and replaced with 1 mL of fresh PBS. The drug concentration in PBS was determined using UV-
Vis and fluorescent spectroscopy, as previously described. 
 
Biological characterisation of nano-aggregates and formulations 
BxPC-3 cells were maintained using RPMI media supplemented with 10% foetal bovine serum and 1% 
penicillin streptomycin. Cells were grown in an incubator at 37 °C and 5% CO2. 
The level of cytotoxicity of PAA-Ox5 and PAA-Ox5-HNP was determined via the 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) assay on BxPC-3 cells over 24 h. Briefly, the cells were seeded into 
96-well plates (15,000 cells/well) and incubated with increasing concentration of polymer solutions (0-0.5 
mgmL-1). The plates were incubated for 24 h before the solutions were removed and cells washed with fresh 
media. MTT solution (50 µL, 5 mgmL-1) was added to the wells and the plate was incubated (37 °C with 5 % 
CO2) in the absence of light for 4 h. The MTT solution was removed and the remaining purple formazan 
complexes dissolved in DMSO (100 μL). The sample absorbance as recorded at 570 nm using a Tecan Pro200 
microplate reader (Tecan, UK). Percentage viability was calculated relative to the positive and negative controls 
(media and Triton-X (1:5 PBS), respectively). Cytotoxicity assays for the anticancer drugs 6-TG and 
BNIPDaoct alone (0.5 – 1x10-6 mgmL-1) and the drug formulations in PAA-Ox5 and PAA-Ox5-HNP polymers 
were carried out. Here, polymer concentration of 0.001 mgmL-1 was used as this was above the IC90 value 
obtained from the previous study. 
Drug uptake studies were carried out after 4 h incubation of the novel formulations of 6-TG and BNIPDaoct. 
Cells were seeded in a 6-well plate (50,000 cells/well) and incubated with 50 µgmL-1 drug concentration (in 
formulation compared with free drug). Plates were incubated for 4 h at 37 °C, 5% CO2 before the media was 
removed and the cells washed three times with phosphate buffered saline (PBS). The cells were trypsinised and 
resuspended in 1 mL media. Cells were counted on a Countess® automated cell counter (Life Technologies, 
UK), 1 x106 cells transferred into an Eppendorf tube and centrifuged at 500 rpm for 5 min. The cell pellet was 
resuspended in deionised water (6-TG)/DMSO (BNIPDaoct) and vortexed for 30 seconds. The sample 
absorbance was recorded at 330 nm for the 6-TG and fluorescence at excitation 240 nm and emission 380 nm 
for the BNIPDaoct. Total drug concentration was calculated per cell in respect to calibration curves. 
 
All statistical analysis was carried out using T-Test analysis within the Microsoft Excel® software package. 
 
Results 
Synthesis and characterisation of PAA-Ox5 
PAA-Ox5 polymers were fabricated via a simple substitution reaction between the primary amines in the parent 
PAA structure and the chloride functionality of the oxadiazole compound (Fig. 1). 1H NMR spectroscopy was 
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used to identify whether polymer synthesis had been successful. The spectra (Fig.2A) showed peaks at δ0.75, δ 
2.50, δ 3.00, δ1.40 and δ 1.50 which can be attributed to the CH2 and CH groups in the homopolymer backbone, 
respectively. Additional peaks identified between at δ7.25-7.75 can be attributed to the aromatic CH groups 
present in the oxadiazole pendant group. The proton on the –SH group of the oxadiazole pendant was not 
observed on this spectra; this is likely to be due to rapid exchange between the thiol and D2O solvent. FTIR 
analysis of the PAA-Ox5 amphiphile was run between 4000 – 650 cm-1 to identify the characteristic functional 
groups present (Fig. 2B). Here, characteristic peaks were observed at 3350 cm-1 and 2800 cm-1 which arise from 
the N-H stretching and C-H stretching in the PAA backbone, respectively. Additional peaks observed at 1900 
cm-1 and 1600 cm-1 indicated that hydrophobic pendant group attachment had been successful due to these peaks 
being attributable to the bending and stretching vibrations of the aromatic ring C=C present in the oxadiazole 
structure. Elemental analysis was used to quantitatively determine the degree of molar substitution of oxadiazole 
onto the PAA backbone. The data suggested that 5.8% grafting had occurred; which was calculated from 
relative sulphur content (Table 1). 
Synthesis and characterisation of HNPs 
Fe3O4 magnetic nanoparticles were successfully synthesised using a common precipitation protocol [28,47]. The 
polymers were subsequently electrostatically coated with PEI before gold coating. Each stage of the reaction 
was closely monitored using UV-Vis-NIR spectroscopy (Supplementary Data, Figure 1), photon correlation 
spectroscopy and zeta potential measurement (Table 1). The Fe3O4 nanoparticles possessed an inherent negative 
charge due to sulphate association attributed to the reaction pathway. After addition of the PEI onto the Fe3O4 
surface, forming Fe3O4-PEI the charge increased from -17.2 mV to +50.2 mV; this large increase in surface 
charge is indicative of successful polymer attachment, due to the polycationic nature of PEI. After gold seeding 
and final coating the zeta potential dropped to +32.4 mV and +19.1 mV (Table 1) due to the electronegative 
charge on the colloidal gold. The final particles were visualised using TEM (Supplementary Data, Figure 2) and 
the particle diameter was determined to be 50 nm. Magnetic measurements were carried out using SQUID 
measurement. Here, the magnetization vs. applied field hysteresis loop was determined at 250K (Fig. 3A1). The 
magnetic coercivity and saturation magnetization data obtained indicate that highly crystalline Fe3O4 cores are 
present in the HNP structure which shows a high degree of order at room temperature. The zero field 
cooled/field cooled curve (Fig. 3A2) data shows the typical trend for ferromagnetic nanoparticles. The absence 
of a maximum in this data shows that the ordering temperature is above room temperature (25oC). 
Characterisation of PAA-Ox5 and PAA-Ox5-HNP nano-aggregates 
Nano-aggregates were formed upon probe sonication of the PAA amphiphiles in deionised water. The 
amphiphiles were characterised using TEM, PCS and zeta potential measurement. The TEM image (Fig. 1B1) 
of the PAA-Ox5 aggregates shows micellar-like structures of approximately 47 nm in diameter which is smaller 
than the diameter gained through PCS measurement (72 nm), however; this is due to different sample 
preparation and measurement techniques. The TEM measures dried samples whereas, the PCS measures the 
hydrodynamic radius of the aggregates suspended in water, hence obtaining a larger value. The polydispersity 
index (PDI) of the PAA-Ox5 was 0.330 indicating that the nano-aggregates were not totally monodisperse. A 
highly positive zeta potential measurement was obtained for this amphiphile (+41.9 mV) which is unsurprising 
due to the amine functionality within the parent PAA backbone.  
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HNP conjugation was achieved through dative covalent linkage between the colloidal gold surface of the HNP 
and the thiol functionality in the oxadiazole pendant group of the PAA-Ox5. It is believed that only one –SH 
group will be attached to one HNP due to the effects of steric hindrance coupled with the low concentration of 
HNPs added in the reaction. The TEM image (Fig. 1B2) indicates that attachment was successful. Here, nano-
aggregate clusters are observed with small dense regions within the nano-aggregate core due to HNP attachment 
onto the randomly grafted oxadiazole pendants forming PAA-Ox5-HNP. After conjugation a sharp decrease in 
surface charge was observed, with the zeta potential decreasing to +19.1 mV. This decrease is possibly due to 
the incorporation of the HNPs which may still become visible to the instrument when the aggregates are forming 
and disrupting under dynamic equilibrium. An increase in hydrodynamic radius (235 nm) and TEM particle 
diameter (175 nm) was observed which indicates that after HNP incorporation, the aggregates are no longer 
capable of forming compact aggregates, possibly due to steric hindrance within the hydrophobic core. 
Interestingly, a decrease in PDI from 0.330 (PAA-Ox5) to 0.125 (PAA-Ox5-HNP) occurred. This indicates that 
an increase in aggregate monodispersity occurs; perhaps due to the HNP hindering intramolecular aggregate 
formation, due to steric hindrance compared with the intermolecular aggregation of larger, less compact PAA-
Ox5-HNP aggregates. Interestingly, a clear structure was evident in the PAA-Ox5 TEM (Fig.1B1) however, the 
PAA-Ox5-HNP TEM (Fig.1B2) lacked definition. Perhaps the presence of the electron dense HNPs hinders the 
ability to determine accurate definition to the external polymer aggregate surfaces. The clusters of the PAA-
Ox5-HNP aggregates observed, is due to the inherent magnetic properties of the HNPs. Hence, in the drying 
process for the TEM the aggregates slowly aggregate towards each other before the droplet of water is 
completely dried. This is to be expected with any magnetic nano-material being prepared and imaged in this 
manner. SQUID analysis showed that the polymer construct possessed magnetic properties which further 
confirmed the HNP conjugation was successful (Fig. 3B). The signals obtained for M vs. T of the PAA-Ox5-
HNP (Fig. 3B2) were understandably much smaller than for the HNPs alone (Fig. 3A2) (10-12 compared with 
10-10); this was due to only 5% of the total mass of the amphiphile being composed of HNPs. 
The CAC was determined for both amphiphiles using a hydrophobic methyl orange UV probe (Fig. 4). Here, a 
hypsochromic shift was observed in the λmax values for absorbance in the UV spectra. The inflection point at the 
beginning of the curve of λmax vs. polymer concentration is indicative of the CAC value [10]. The PAA-Ox5 
exhibited a CAC value at 0.093 mgmL-1 which decreased to 0.049 mgmL-1 after HNP attachment (PAA-Ox5-
HNP). This decrease in CAC value suggests that HNP addition changes the degree of hydrophobic interaction 
between the oxadiazole pendant groups and, hence, reduced concentrations are required for aggregate formation.  
 
Drug loading and in vitro drug release from nano-aggregates 
The model hydrophobic drugs propofol and griseofulvin were incorporated into the nano-aggregate structure via 
hydrophobic-hydrophobic interactions (Fig. 5).  Polymer concentration and initial drug:polymer feed ratio were 
varied in order to determine the optimal drug loading parameters. Optimal drug loading for both propofol and 
griseofulvin was achieved at the 6 mgmL-1 polymer concentration and 10:1 initial drug:polymer feed ratio 
(Supplementary data, Fig. 3). Both PAA-Ox5 and PAA-Ox5-HNP amphiphiles showed a polymer concentration 
and initial drug-feed dependant trend on drug solubilisation. Interestingly, the PAA-Ox5-HNP nanoparticles 
were consistently capable of higher drug encapsulation within their hydrophobic core; this could be due to the 
less compact nature of the aggregates accommodating a larger quantity of drug molecules (Table 2). The 
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aqueous solubility of propofol was increased by 137-fold and 250-fold with the PAA-Ox5 and PAA-Ox5-HNP 
aggregates, respectively.   Encapsulation efficiencies were 22.8% and 43% and drug loading capacities were 
229% and 430% for PAA-Ox5 and PAA-Ox5-HNP, respectively. Core expansion was observed upon drug 
loading; TEM images showed that the aggregates increased in size from 47 nm to 200 nm, and 175 nm to 388 
nm, between unloaded and drug loaded aggregates, respectively (Fig. 1B and Fig. 6A1andA2). A similar trend 
was observed in the hydrodynamic diameter measurements resulting from photon correlation spectroscopy 
(Table 1). The FTIR spectra of the freeze dried formulation (Supplementary data, Fig. 4A) showed the presence 
of an additional O-H peak at 3600 cm-1 compared with the unloaded polymers (Fig. 2B), and the ortho-
substituted benzene ring peaks at 748 cm-1 were due to the substitution pattern of the functional groups present 
on the propofol moiety; this indicated that propofol had been successfully encapsulated in the formulation. The 
griseofulvin solubility studies showed that PAA-Ox5 and PAA-Ox5-HNP amphiphiles increased drug solubility 
by 53-fold and 56-fold, respectively, when compared with the intrinsic drug solubility. This resulted in 1.59 
mgmL-1 and 1.68 mgmL-1 total drug solubilisation (Table 2). Here, the encapsulation efficiency was reduced 
when compared with the propofol study.  However, griseofulvin is a relatively much larger molecule (molecular 
weight = 353 gmol-1) compared to propofol (molecular weight = 178 gmol-1). Similar to the propofol study, 
nano-aggregate core expansion was observed upon drug loading when visualised using TEM (Fig. 6A2andB2). 
The FTIR spectra of the griseofulvin formulations showed extra peaks at 3359 cm-1 (O-H), 1650 cm-1 (C=O), 
800 cm-1 (substituted benzene) and a weak peak at 550 cm-1 (Supplementary data, Fig. 4B). These peaks 
correlate well with the functional groups present on the griseofulvin moiety. 
The novel anticancer agent BNIPDaoct was loaded into the PAA-Ox5 and PAA-Ox5-HNP aggregates using the 
optimal parameters identified from the propofol and griseofulvin studies (Polymer concentration 6 mgmL-1, 
drug: polymer feed 10:1). BNIPDaoct (molecular weight = 781 gmol-1) is from a family of bisnaphthalimide 
compounds which have shown potential in cancer therapy. However, this specific analogue is hindered by its 
extremely hydrophobic nature, so much so in fact, that no measurable intrinsic aqueous solubility could be 
measured using the HPLC (coupled to a fluorescent detector) used in this study. Therefore, any increase in drug 
solubility is desirable. Once loaded into the respective PAA amphiphiles (PAA-Ox5 and PAA-Ox5-HNP), 0.84 
mgmL-1 and 0.92 mgmL-1 drug solubilisation was achieved. These values are somewhat lower than those 
achieved with propofol and griseofulvin. However, worthy of note, is that BNIPDaoct is a more sterically 
demanding molecule and therefore less drug may be capable of being physically accommodated within the 
nano-aggregate core. Interestingly, the TEM images in Fig. 6A3andB3 show spherical and uniform nano-
aggregates compared with the other two formulations where irregular shaped aggregates were observed. A final 
study was also carried out using the hydrophilic anticancer agent 6-TG. Here, the rationale was to permanently 
conjugate the drug molecule to the HNP incorporated into the structure of the PAA-Ox5-HNP. Due to the 
hydrophilic nature of 6-TG, the mode of drug incorporation had to be achieved via a different mechanism to the 
previous studies, since no hydrophobic-hydrophobic interactions would occur (Fig. 5B). A study was carried out 
using the PAA-Ox5 merely as a control. As expected, the data obtained showed an increased drug concentration 
present within the PAA-Ox5-HNP core (2.8 mgmL-1) when compared with 0.5 mgmL-1 in the PAA-Ox5 (Table 
2); this was a 5-fold increase. The drug concentration encapsulated inside the PAA-Ox5 is probably due to the 
drug molecules being dissolved in the surrounding aqueous media and not due to physical entrapment within the 
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hydrophobic core. The TEM images show that core expansion upon drug loading only occurred in the PAA-
Ox5-HNP and not the PAA-Ox5 non-metallic amphiphile) (Fig. 6A4andB4). 
In vitro drug release studies were carried out under ‘sink conditions’ for all of the optimal formulations (Fig. 7). 
The studies were carried out over a period of 72 hrs. All of the hydrophobic drug formulations showed an initial 
‘burst’ release over the first 4 hr period. Propofol was released consistently throughout the study period until 
100% had been released at 72 hrs. Interestingly, the PAA amphiphiles containing the HNPs demonstrated 
slower drug release profiles compared with the PAA-Ox5. Griseofulvin and BNIPDaoct release followed similar 
trends whereby, after the initial burst phase, a plateau was observed. Across all drugs, the PAA-Ox5 and PAA-
Ox5-HNP formulations released 100% and 74% of drug over the 72 h study period, respectively. The 
BNIPDaoct-loaded aggregates however, only released 25% (PAA-Ox5) and 18% (PAA-Ox5-HNP) of total drug 
payload over the time tested, respectively. This was not a surprise, given the extremely hydrophobic nature of 
the drug molecule which leads to it being energetically more favourable for the drug to reside within the 
hydrophobic core compared to release into the aqueous phase.  Interestingly, a diametric drug release profile 
was observed for 6-TG between the two amphiphile derivatives. That is, the PAA-Ox5 formulation showed a 
100% total drug release after 5 min. This confirms that the reported drug concentration was not, in fact, due to 
physical entrapment, but was due to the water-soluble drug being freely dissolved in the aqueous media. Thus, 
in just 5 min, drug diffusion from the formulation (in dialysis tubing) into the surrounding PBS had occurred. In 
contrast to this result, only 2% of 6-TG content was released from the PAA-Ox5-HNP formulation. Since the 
drug incorporation was not due to hydrophobic-hydrophobic interactions but was, rather, due to permanent 
covalent attachment, it may appear odd that any drug was released at all. However, taking into account the small 
amount of 6-TG freely dissolved in the aqueous media of the formulation (and not physically attached), this 
result seems reasonable.  
 
Biological characterisation of nano-aggregates and novel formulations 
The cytotoxicity of the novel PAA amphiphiles on human pancreatic adenocarcinoma (BxPC-3) cells was 
determined using an MTT assay. The unloaded nano-aggregates were incubated with the cells for 24 hr and the 
total cell viability estimated compared to control wells. Upon incubation, the data showed that 50% of the total 
cell number was viable (IC50) at 60 µgmL-1 (PAA-Ox5) and 55 µgmL-1 (PAA-Ox5-HNP), respectively. These 
similar values indicated that the incorporation of the metallic HNPs into the polymer backbone did not result in 
any significant increase in toxicity (p>0.001). MTT assays were carried out on PAA-Ox5 and PAA-Ox5-HNP 
formulations of BNIPDoact and 6-TG to determine whether the polymeric self-assemblies were capable of 
delivering cytotoxic drugs into the cells, thus enhancing their therapeutic effect. To determine whether the 
formulations enhanced the therapeutic effect of their anticancer agent, they were formulated at the polymer IC90 
concentration (the concentration at which 90% of cells were viable). It is therefore assumed that a negligible 
cytotoxic effect occurs due to the polymer itself. Hence, any change in the IC50 value with the polymeric 
formulations (compared with the free drug) is as a result of an increased drug uptake or enhanced therapeutic 
effect. The novel formulations encapsulating BNIPDaoct were capable of a 10-fold (PAA-Ox5) and 13-fold 
(PAA-Ox5-HNP) decrease in IC50 value compared with the free drug (dissolved in DMSO), respectively (Fig. 
8A). This data therefore indicates that the incorporation of BNIPDaoct into PAA nano-aggregates can enhance 
its therapeutic effect. Drug loading studies were carried out and the total drug content quantified per cell (Fig. 
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8B). Here, the results showed that after only 4 hr, 83-fold more drug had entered the cells in the PAA-Ox5 
compared with the free drug. Additionally, 104-fold more drug was present inside the BxPC-3 cells when 
incubated with the PAA-Ox5-HNP formulation. This significant increase in cellular internalisation is probably 
the major contributing factor to the large decrease in cell viability and IC50 value after 24 hr (p<0.001). 
Interestingly, a similar trend was observed in the PAA-Ox5-HNP formulation containing 6-TG. Here, a 
significant (p<0.001) 455-fold increase in drug uptake was observed after the 4h incubation period and a 21-fold 
decrease in IC50 was recorded. The PAA-Ox5 formulation resulted in a 4-fold increase in cellular drug uptake 
and 1-fold decrease in IC50, neither of which were statistically significant (p>0.001). 
 
Discussion 
Nanoparticulate drug delivery systems have been widely studied over the past decade. With ever-increasing 
knowledge and understanding, more sophisticated platforms are continually emerging – as this study 
demonstrates. Incorporation of HNPs into the amphiphilic polymer architecture results in bi-functional 
aggregates capable of simultaneous imaging and drug delivery. This study investigated the potential for 
incorporation of metallic HNPs into an amphiphilic graft polymer structure and the resultant physicochemical 
and biological effects this functionalization had.  Previous work investigating HNPs as drug carriers has mainly 
focussed on surface conjugation of the drug to the particles [29,48]. In this study, we successfully synthesised 
both PAA-Ox5 amphiphile derivatives which were characterised by elemental analysis, 1H NMR and FTIR (Fig. 
2). Iron oxide nanoparticles were synthesised via wet chemical precipitation and coated with gold using an 
organic intermediate (PEI). These nanoparticles were successfully incorporated into the polymer structure via 
dative covalent bonding between the gold surface and thiol functionality of the oxadiazole pendant group. TEM, 
zeta potential measurement and SQUID analysis confirmed the presence of the HNPs on the polymer backbone 
(Fig. 1B, Table 1, Fig. 3B). Nano-aggregates formed spontaneously in the aqueous environment and were 
characterised by PCS and TEM and their CAC determined using a hydrophobic methyl orange probe (Fig. 4). 
The addition of the HNPs into the intrinsic polymer structure (PAA-Ox5-HNP) resulted in larger nano-
aggregates which possessed lower CAC values (0.049 mgmL-1) compared to the PAA-Ox5 polymer (0.093 
mgmL-1). These values are comparable with other CAC studies using methyl orange. In 2008, Thompson and 
colleagues fabricated PAA amphiphiles conjugated with cholesterol, palmitoyl, cetyl and quaternary ammonium 
groups in 2.5-5% mole grafting ratios [6]. Here, they reported CAC values between 0.02 mgmL-1-0.18 mgmL-1 
which were dependant on the polymer architecture [6]. In a similar study, PAA conjugated with the hydrophobic 
pendant groups 9-Fluorenylmethoxy carbonyl (Fmoc), Dansyl and naphtholyl (Naphth) in 5% and 10% mole 
grafting ratios achieved CAC values of between 0.125 -0.5 mgmL-1 [11].  Our cytotoxicity studies of the PAA 
derivatives indicated IC50 values of 60 µgmL-1 and 55 µgmL-1 for PAA-Ox5 and PAA-Ox5-HNP, respectively 
(Fig. 8A). Here, the IC50 values for both amphiphiles are not significantly different (p>0.001). This work 
follows the extensive investigations into the stability and toxicity of HNPs in BxPC-3 cells that have been 
reported recently [29]. This study showed that over a 2 week period the HNPs appeared to be chemically stabile 
in physiological media (pH 4.6 and 7.2). No significant cell viability reduction was observed in the BxPC-3 
cells after 1 week incubation up to 100 µgmL-1. In addition, negligible cell membrane damage or free radical 
production was detected after 72 h incubations up to 25 µgmL-1 [29].  
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Drug incorporation into the nano-aggregates was achieved by two mechanisms. Firstly, hydrophobic drug 
molecules are encapsulated within the hydrophobic core of the aggregates due to the preferential reduction in 
Gibbs’ free energy (Fig. 5A). Here, two model hydrophobic drugs, propofol and griseofulvin were used in order 
to investigate the optimal parameters, which included the polymer concentration and initial drug: polymer mass 
feed ratio for drug encapsulation to occur. Using the optimal formulation conditions identified in these studies (6 
mgmL-1 polymer concentration and 10:1 initial drug:polymer feed ratio), an additional hydrophobic drug 
(BNIPDaoct) was investigated and incorporated into the core of the PAA amphiphiles in a similar manner 
(Supplementary data, Figure 3). Our drug solubilisation results were in agreement with previous studies on the 
drug loading of PAA amphiphiles [13]. Further, the PAA derivatives tested proved to be universal drug 
solubilizers for a range of hydrophobic drugs. The maximum solubilisation concentrations were recorded as 
25.79 mgmL-1, 1.68 mgmL-1 and 0.92 mgmL-1 for propofol, griseofulvin and BNIPDaoct, respectively (Table 
2). Interestingly, these loading maxima were all achieved with the PAA-Ox5-HNP amphiphile. Perhaps, the less 
compacted core resulted in greater core expansion and thus drug accommodation resulting in greater drug 
loading and encapsulation efficiencies (Table 2). Previous studies using PAA amphiphiles with Dansyl pendant 
groups (with 10% mole grafting) reported maximum drug solubilisation of 22.4 mgmL-1 and 16.71 mgmL-1 for 
propofol and griseofulvin, respectively [13]. Here, the propofol results are comparable to ours at lower molar 
pendant grafting levels (5%) with the oxadiazole group, however, our griseofulvin solubilisation results are 
notably lower.  The reason for this is not clear, although it could be due to the increased core expansion upon 
drug loading resulting in larger aggregates which were then removed during the filtering process. Other studies 
reported cholesterol modified PAA (Ch5) for BNIPDaoct solubilisation achieved 0.3 mgmL-1 drug 
encapsulation with 1 mgmL-1 polymer concentration, 5% mole cholesterol grafting and a 1:1 initial 
drug:polymer mass feed ratio [49]. Here, the PAA-Ox5-HNP formulation achieved a greater drug loading (0.9 
mgmL-1) but with a lower % loading capacity (15% compared to the 30%) to the Ch5-BNIPDaoct formulation. 
The second mechanism of drug incorporation concerned the conjugation of the model hydrophilic drug 6-TG 
onto PAA-Ox5-HNP amphiphile (via the HNP) (Fig. 5B). This was achieved through dative covalent linkage 
between the colloidal gold surface and the thiol moiety in the 6-TG structure. 6-TG is a freely water-soluble 
drug and therefore encapsulation via hydrophobic-hydrophobic interaction should not occur; hence, PAA-Ox5 
was used as a control vehicle. The conjugation of 6-TG onto the PAA-Ox5-HNP structure could possibly protect 
the drug on its journey to target site and reduce undesirable side effects. Here, the data showed an exciting 
solubility increase to 2.8 mgmL-1 with PAA-Ox5-HNP compared with 0.5 mgmL-1 with PAA-Ox5. This 
indicates that the drug had successfully incorporated into the HNP-amphiphile structure which was also 
confirmed with an increase in nano-aggregate diameter using TEM (Fig. 6B4).  
Biological investigations into the BNIPDaoct and 6-TG formulations showed consistently that greater cell 
uptake occurred after 4 h incubation with BxPC-3 cells compared with free drug. This exciting finding is in 
agreement with other studies which have shown that drugs either encapsulated or physically conjugated onto 
nanoparticulates experience enhanced cellular uptake [50]. Other work in BxPC-3 cells investigated the cellular 
response to 6-TG after its conjugation to the HNPs onto HNP surface showed enhanced cellular uptake of the 
conjugated 6-TG when compared with free drug with a resulting 10-fold decrease in IC50 [29]. At these drug 
concentrations the polymer level is below its CAC. However, the added hydrophobicity of the drug molecule 
into the intrinsic structure of the nano-aggregate may be enough to stabilize the system. Little is known in this 
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area as previous studies have observed that even at polymer concentrations below IC50 in vivo enhancement in 
drug efficacy occurs [49]. These in vitro studies can only be classed as indicators for in vivo situations and 
further in vivo studies must be carried out to truly deduce the clinical efficacy.  Further, it has been well 
documented that nanoparticulates preferentially accumulate inside the leaky vasculature of rapidly proliferating 
tumour sites which is an example of a passive targeting approach. Hence, this technology could enhance current 
chemotherapeutic strategies by penetrating further into the dense stroma surrounding tumour sites particularly in 
pancreatic cancer. 
 
Conclusion 
Novel PAA-Ox5-HNPs have been successfully synthesised and have demonstrated good potential as drug 
solubilizers / carriers. Our results indicate that after conjugation of metallic HNPs onto the polymer amphiphile 
structure, drug loading is increased with an accompanying decrease in the in vitro drug release rate. In vitro 
biological studies have shown that these novel PAA amphiphile formulations are capable of enhancing the 
efficacy of cancer therapeutics over the free drug. Moving forward, in vivo studies should be carried out in order 
to further elucidate the potential of these polymer constructs for image guided drug delivery. 
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Figures 
 
Figure 1. A) Chemical synthesis of PAA-Ox5 and PAA-Ox5-HNP and B) TEM images of 1) PAA-Ox5 and 2) 
PAA-Ox5-HNP nano-aggregates. 
 
Figure 2. Chemical characterisation of PAA-Ox5. A) 1H NMR spectra in D2O carried out on a 400MHz NMR 
at 25oC and B) FTIR spectra run on a diamond tipped ATR-FTIR (64 scans). 
Figure 3. Magnetization data of A)HNPs and B) PAA-Ox5-HNP. 1) M(T) curves measured in zero-field cooled 
warming and field-cooling mode, 2) M(H) curves collected at 250 K between -4 and 4 MA/m. 
Figure 4. CAC measurement of nano-aggregates using hydrophobic methyl orange probe resulting in a 
hypsochromic shift upon aggregate formation. Samples measured via UV-Vis spectroscopy (n=3, ±SD). 
Figure 5. Mechanism of A) hydrophobic drug molecule encapsulation and B) 6-TG conjugation to PAA-Ox5-
HNP via dative covalent bonding between the thiol and gold surface of the HNP. 
Figure 6. TEM images of optimal formulations of A) PAA-Ox5 and B) PAA-Ox5-HNP nano-aggregates 
incorporating 1) propofol, 2) griseofulvin, 3) 6-TG and 4) BNIPDaoct.  
Figure 7. Drug release from optimal formulations over 72 h. Study carried out in PBS under ‘sink’ conditions at 
37 °C with constant stirring (n=3, ±SD). 
 
Figure 8. Biological investigation on BxPC-3 cells. A) Cytotoxicity evaluation of polymers and formulations 
and B) cellular uptake of 6-TG and BNIPDaoct (n=3, ±SD). * denotes level of significance increase in IC50 
between free drug and formulation (p<0.001). ** denotes level of significance increase in drug uptake between 
free drug and formulation (p<0.001). 
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Tables 
 
Table 1. Physicochemical analysis of PAA, PAA-Ox5 nano-aggregates, HNPs, PAA-Ox5-HNP nano-aggregates 
and optimal drug loading formulations. 
Table 2. Drug loading of PAA amphiphiles with hydrophobic and hydrophilic drug molecules via hydrophobic 
interaction and direct conjugation, respectively (n=3, ±SD). 
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Figure 1. A) Chemical synthesis of PAA-Ox5 and PAA-Ox5-HNP and B) TEM images of 1) PAA-Ox5 and 2) PAA-Ox5-HNP nano-aggregates. 
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Figure 2. Chemical characterisation of PAA-Ox5. A) 1H NMR spectra in D2O carried out on a 400MHz NMR 
at 25oC and B) FTIR spectra run on a diamond tipped ATR-FTIR (64 scans). 
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Figure 3. Magnetization data of A)HNPs and B) PAA-Ox5-HNP. 1) M(T) curves measured in zero-field cooled 
warming and field-cooling mode, 2) M(H) curves collected at 250 K between -4 and 4 MA/m. 
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Figure 4. CAC measurement of nano-aggregates using hydrophobic methyl orange probe resulting in a 
hypsochromic shift upon aggregate formation. Samples measured via UV-Vis spectroscopy (n=3, ±SD). 
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Figure 5. Mechanism of A) hydrophobic drug molecule encapsulation and B) 6-TG conjugation to PAA-Ox5-
HNP via dative covalent bonding between the thiol and gold surface of the HNP. 
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Figure 6. TEM images of optimal formulations of A) PAA-Ox5 and B) PAA-Ox5-HNP nano-aggregates 
incorporating 1) propofol, 2) griseofulvin, 3) 6-TG and 4) BNIPDaoct.  
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Figure 7. Drug release from optimal formulations over 72 h. Study carried out in PBS under ‘sink’ conditions at 
37 °C with constant stirring (n=3, ±SD). 
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Figure 8. Biological investigation on BxPC-3 cells. A) Cytotoxicity evaluation of polymers and formulations 
and B) cellular uptake of 6-TG and BNIPDaoct (n=3, ±SD). * denotes level of significance increase in IC50 
between free drug and formulation (p<0.001). ** denotes level of significance increase in drug uptake between 
free drug and formulation (p<0.001). 
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Table 1. Physicochemical analysis of PAA, PAA-Ox5 nano-aggregates, HNPs, PAA-Ox5-HNP nano-aggregates and optimal drug loading formulations. 
Particle Molar grafting level of 
PAA amphiphiles 
(monomer:pendant) 
Metal content  analysis µgmL-1 Size nm (±SD) 
from TEM 
Size nm (±SD) from 
PCS 
PDI (±SD) Zeta potential 
mV (±SD) 
Fe  
 Au 
PAA 1:0.000 - - - - - - 
PAA-Ox5 1:0.058 - - 47 (0.5) 72 (0.680) 0.330 (0.026) +41.9 (3.282) 
Fe3O4 - 5215 - 50 (0.5) 2159 (154.0) 0.675 (0.012) -17.2 (1.000) 
Fe3O4-PEI - 2651 - 55 (1.0) 208 (7.125) 0.321 (0.012) +50.2 (3.052) 
Fe3O4-PEI-AuSEED - 1002 59 60 (0.5) 201 (12.245) 0.372 (0.004) +32.4 (2.001) 
Fe3O4-PEI-AuCOAT (HNP) - 852 218 70 (0.5) 124 (12.221) 0.114 (0.002) +12.2 (1.051) 
PAA-Ox5-HNP 1:0.058 50 7 175 (1.5) 235 (2.152) 0.125 (0.012) +19.1 (1.498) 
PAA-Ox5-Propofol 1:0.058 - - 200 (2.5) 514 (3.215) 0.463 (0.178) +48.4 (3.792) 
PAA-Ox5-HNP-Propofol 1:0.058 50 7 388 (5.0) 526 (2.541) 0.237 (0.014) +39.1 (3.064) 
PAA-Ox5-Griseofulvin 1:0.058 - - 133 (0.5) 162 (2.702) 0.151 (0.005) +25.0 (3.276) 
PAA-Ox5-HNP-Griseofulvin 1:0.058 50 7 200 (0.5) 261 (0.798) 0.814 (0.072) +31.6 (2.479) 
PAA-Ox5-BNIPDaoct 1:0.058 - - 167 (3.5) 109 (2.554) 0.341 (0.069) +35.5 (2.783) 
PAA-Ox5-HNP-BNIPDaoct 1:0.058 50 7 222 (1.5) 206 (4.771) 0.222 (0.019) +14.3 (1.118) 
PAA-Ox5-6TG 1:0.058 - - 55 (1.0) 157 (3.045) 0.175 (0.010) +38.9 (3.051) 
PAA-Ox5-HNP-6TG 1:0.058 50 7 250 (1.5) 313 (2.352) 0.455 (0.003) +33.9 (2.659 
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Table 2. Drug loading of PAA amphiphiles with hydrophobic and hydrophilic drug molecules via hydrophobic interaction and direct conjugation, respectively (n=3, ±SD). 
Polymer Polymer 
concentration 
mgmL-1 
Drug Incorporation 
mechanism 
Initial drug feed: 
polymer ratio 
 Maximum drug 
loading 
concentration 
mgmL-1 (n=3, ±SD) 
Increment 
increase from 
aqueous 
solubility (- fold) 
Excipient: 
Drug ratio 
% EE %LC 
PAA-Ox5 6 
 
Propofol Electrostatic 10:1 
 
13.71 (0.013) 137 0.44 22.8 229 
6 
 
Griseofulvin Electrostatic 10:1 
 
1.59 (0.002) 53 3.78 2.7 27 
6 
 
BNIPDaoct Electrostatic 10:1 0.84 (0.102) - 7.14 1.4 14 
6 
 
6-TG Conjugation 10:1 0.5 (0.012) - 12 0.8 8.3 
PAA-Ox5-HNP 6 
 
Propofol Electrostatic 10:1 
 
25.79 (0.035) 250 0.23 43 430 
6 
 
Griseofulvin Electrostatic 10:1 
 
1.68 (0.064) 56 3.57 2.8 28 
6 BNIPDaoct Electrostatic 
 
10:1 0.92 (0.111) - 6.52 1.5 15 
6 6-TG Conjugation 10:1 
 
2.8 (0.102) - 2.14 4.7 47 
